Brain diagnostics innovator BrainScope has secured new investment from the Alzheimer’s Drug Discovery Foundation (ADDF) as part of its ongoing Series B equity financing round. This investment will support the development of an Artificial Intelligence / Machine Learning-derived brain-activity-based biomarker aimed at predicting the future onset of Alzheimer’s disease. Additionally, BrainScope is exploring whether its FDA-cleared brain bleed biomarker, originally designed for trauma-related applications, could effectively detect ARIAs, a serious side effect of newly FDA-approved Alzheimer’s drugs. The goal is to potentially help patients avoid the expensive and time-consuming multiple MRI scans currently recommended for ARIAs.

According to Miles Gilburne, Chairman of the Board of BrainScope, the global market for Alzheimer’s disease treatments is expected to exceed $13 billion by 2030. BrainScope is seeking collaboration partnerships with Alzheimer’s-focused drug companies to enhance patient selection for clinical trials and provide companion diagnostics for monitoring side effects. The addition of new board members, including Michael A. Epstein, Richard A. Miller MD, and Ralph Terkowitz, was also announced. Mr. Epstein is set to assume the role of Chairman on October 1, 2023.